| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Dyne Therapeutics, Inc. | Chief Commercial Officer | Common Stock | 58.4K | $2.68M | $45.81 | Sep 3, 2024 | Direct |
| Vir Biotechnology, Inc. | EVP & Chief Operating Officer | Common Stock | 149K | $227K | $1.53 | Mar 3, 2023 | Direct |
| Vir Biotechnology, Inc. | EVP & Chief Operating Officer | Stock Option (Right to Buy) | 70K | $107K | $1.53 | Feb 22, 2023 | Direct |
| Dyne Therapeutics, Inc. | Chief Commercial Officer | Stock Option (Right to Buy) | 185K | Sep 3, 2024 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| DYN | Dyne Therapeutics, Inc. | Sep 3, 2024 | 0 | $0 | 3 | Sep 3, 2024 | Chief Commercial Officer |
| DYN | Dyne Therapeutics, Inc. | Sep 3, 2024 | 2 | $0 | 4 | Sep 3, 2024 | Chief Commercial Officer |
| VIR | Vir Biotechnology, Inc. | Mar 3, 2023 | 1 | -$33.8K | 4 | Mar 7, 2023 | EVP & Chief Operating Officer |
| VIR | Vir Biotechnology, Inc. | Feb 22, 2023 | 2 | $0 | 4 | Feb 24, 2023 | EVP & Chief Operating Officer |
| VIR | Vir Biotechnology, Inc. | Mar 2, 2022 | 2 | $0 | 4 | Mar 8, 2022 | Chief Business Officer, Global |
| VIR | Vir Biotechnology, Inc. | Mar 2, 2022 | 0 | $0 | 3 | Mar 8, 2022 | Chief Business Officer, Global |